Primary Health Care Corporation

phcc.qa

Welcome to the page of Primary Health Care Corporation. PHCC is dedicated to providing the people of Qatar with highest level of health care by operating and managing different Health Centers across the state of Qatar. Currently, the Primary Health Care Corporation is operating through 23 primary health care centers distributed into three regions, namely Central, Western, and Northern. Thirteen of these centers are located in Doha city, while the rest of centers are located in populated areas in all parts of the country in order to provide a wide variety of different types of health care services that depend on the location and needs of each area throughout a set of objectives which focuses on keeping the health of population, and prevention from diseases, in addition to patient Diagnose and treatment, and the provision of a long-term and constant support to patients and their families from infants to elderly, children, adults, married couples, and mothers.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

ENTOS PHARMACEUTICALS ANNOUNCES SENIOR LEADERSHIP APPOINTMENTS TO EXPAND EXECUTIVE TEAM AND ACCELERATE GROWTH

Entos Pharmaceuticals | March 07, 2022

news image

EDMONTON, Alberta Entos Pharmaceuticals a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced two executive-level appointments, Dr. Steve Chen as Chief Medical Officer (CMO) and Jason Ding as Chief Business Officer (CBO). Dr. Steve Chen brings over 20 years of academic research and pharmaceutical biotechnology experience across multiple therapeutic areas to Entos. He will be ...

Read More

Business Insights

ALNYLAM ANNOUNCES 3-MONTH EXTENSION OF REVIEW PERIOD FOR NEW DRUG APPLICATION FOR VUTRISIRAN

Alnylam Pharmaceuticals, Inc. | April 05, 2022

news image

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has extended the review timeline of the New Drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam recently learned that the original third-party secondary packaging and l...

Read More

Pharma Tech

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19

Pfizer | November 10, 2020

news image

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...

Read More

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

news image

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More
news image

Pharmacy Market

ENTOS PHARMACEUTICALS ANNOUNCES SENIOR LEADERSHIP APPOINTMENTS TO EXPAND EXECUTIVE TEAM AND ACCELERATE GROWTH

Entos Pharmaceuticals | March 07, 2022

EDMONTON, Alberta Entos Pharmaceuticals a clinical-stage biotechnology company developing genetic medicines with its Fusogenix proteolipid vehicle (PLV) nucleic acid delivery platform, today announced two executive-level appointments, Dr. Steve Chen as Chief Medical Officer (CMO) and Jason Ding as Chief Business Officer (CBO). Dr. Steve Chen brings over 20 years of academic research and pharmaceutical biotechnology experience across multiple therapeutic areas to Entos. He will be ...

Read More
news image

Business Insights

ALNYLAM ANNOUNCES 3-MONTH EXTENSION OF REVIEW PERIOD FOR NEW DRUG APPLICATION FOR VUTRISIRAN

Alnylam Pharmaceuticals, Inc. | April 05, 2022

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has extended the review timeline of the New Drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam recently learned that the original third-party secondary packaging and l...

Read More
news image

Pharma Tech

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19

Pfizer | November 10, 2020

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examinat...

Read More
news image

Business Insights

COLUBRISMX, INC. ANNOUNCES CORPORATE REBRANDING TO ENDOQUEST ROBOTICS™

ColubrisMX | July 01, 2022

ColubrisMX, Inc., developer of the world's first flexible endoluminal robotic system which enables scar-free and less invasive surgical procedures, announced that the Company has rebranded to ENDOQUEST Robotics™. The Company also announced the simultaneous launch of its new website, www.endoquestrobotics.com. "Since being founded, our company has made rapid progress in the development of technologies that represent historic advances in endolumi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us